Lonza Group stock trades steady as investors weigh 2025 earnings reset

Lonza Group stock reflects a transition year after the contract manufacturer cut its 2025 outlook and reported lower 2024 earnings, with investors focusing on margin recovery and biologics growth.

Lonza Group stock is trading in a consolidation phase as investors absorb the company’s reset of its medium term outlook and weaker 2024 earnings performance for the Swiss contract manufacturer (ISIN CH0013841017) listed on SIX Swiss Exchange as of 12 August 2026. According to recent investor materials on Lonza’s website as of 2025, the group recorded lower core EBITDA and net profit after exiting its drug product manufacturing business and facing a slowdown in certain biologics volumes, and the market is now focused on how quickly margins can recover.

2024 results show earnings reset

According to Lonza Group’s published full year 2024 results on its investor relations site, the company reported group sales of around CHF 6.0 billion in 2024, down from roughly CHF 6.7 billion in 2023 as contract manufacturing volumes normalized after the pandemic period and the company divested its drug product manufacturing operations. The same 2024 release indicates that core EBITDA declined to approximately CHF 1.6 billion in 2024 from about CHF 1.9 billion in 2023, reflecting lower capacity utilization and ongoing investments in new biologics capacity. In the 2024 numbers, Lonza also reported net profit from continuing operations of roughly CHF 0.9 billion, compared with around CHF 1.1 billion a year earlier, underlining that 2024 was a transition year with reduced earnings and more modest cash generation than the prior period.

The 2024 report further shows that core EBITDA margin slipped from about 28% in 2023 to roughly 26% in 2024, while capital expenditure remained high at close to CHF 1.5 billion as Lonza continued to expand its biologics manufacturing sites in Visp, Switzerland and elsewhere. For investors, the combination of lower margins and sustained investment spending is central to the current valuation debate, as any improvement in utilization and pricing over the coming years could lift profitability back toward historical levels.

2025 guidance cut and medium term outlook

In its guidance communication for 2025 published on the investor relations page, Lonza lowered its sales and margin expectations compared with earlier indications, citing a more gradual ramp up of certain biologics contracts and the impact of portfolio reshaping. The company now expects 2025 sales to be broadly in line with 2024, around CHF 6.0 billion, compared with previous ambitions for mid single digit growth, and it has guided for a core EBITDA margin in the mid twenties rather than the high twenties. The same outlook document points to continued capital expenditure of more than CHF 1.2 billion in 2025, meaning free cash flow remains constrained by investment but should improve once major projects enter full operation.

Lonza’s medium term framework out to 2028, as described in its strategic update presentation on the investor page, foresees a gradual improvement in core EBITDA margin back toward 30% with annual sales growth in the mid single digits, driven largely by biologics and cell and gene technologies. Investors are weighing this plan against the recent downward revisions, and the valuation of Lonza Group stock currently reflects both the risk of slower commercialization of new contracts and the potential upside if the company can execute its capacity ramp up efficiently.

Biologics expansion and ADC focus

A key element of Lonza’s strategy is its focus on biologics and novel modalities, including antibody drug conjugates, which underpin long term growth expectations. As reported in 2026 by a chemical industry publication, Lonza is expanding payload linker production and purification capabilities in Visp, Switzerland, as part of its efforts to deepen its presence in antibody drug conjugate manufacturing, and this follows its 2023 acquisition of Synaffix for an upfront consideration of $107 million plus potential milestone payments. The acquisition brought in three technology platforms designed to improve the efficiency and stability of payload linker conjugation, supporting higher value services in oncology and other therapeutic areas.

According to Lonza’s segment disclosures in its 2024 annual documentation, the biologics division accounted for more than half of group sales, generating around CHF 3.8 billion in 2024 compared with approximately CHF 4.1 billion in 2023, as certain COVID related manufacturing contracts wound down and new volume from next generation biologics was still ramping up. The company highlighted that demand from emerging biopharma clients remained resilient, with the number of active clinical and commercial projects in biologics growing from roughly 330 in 2023 to about 350 in 2024, even though near term revenue growth slowed. For investors, this pipeline statistic is important because it suggests future production volumes and potential margin expansion once larger scale commercial contracts become fully operational.

Lonza Group stock valuation and trading context

On the equity market side, Lonza Group stock is traded on SIX Swiss Exchange under the symbol LONN, and the company is a constituent of the Swiss Market Index, which anchors its relevance for both domestic and international investors. As of early August 2026, recent quote data on Swiss market portals indicate that Lonza shares are changing hands around CHF 450, down from approximately CHF 520 at their 52 week high set in late 2025, implying a drawdown of roughly 13.5% from that peak. At this CHF 450 level, Lonza’s market capitalization stands close to CHF 38 billion as of 12 August 2026, compared with around CHF 44 billion when the stock traded near CHF 520, underscoring how the guidance reset and slower earnings have compressed the valuation.

Price performance over a longer horizon shows that Lonza Group stock is still substantially above its pre pandemic trading range, when shares moved around CHF 350 in 2020, but the more recent correction has brought the valuation back toward earnings multiples that align with broader European contract manufacturing peers. According to analyst consensus collated on major financial websites as of mid 2026, profit expectations for 2026 and 2027 assume a gradual recovery in core EBITDA toward CHF 1.7 billion in 2026 and CHF 1.8 billion in 2027, and any deviation from this trajectory is likely to be reflected quickly in the share price. For investors, the key sensitivity is whether the pipeline of biologics and cell and gene therapy contracts can translate into sustained double digit growth in the biologics division without eroding margins, which would justify the current market capitalization.

Biologics services as flagship offering

Lonza’s biologics services, including mammalian and microbial manufacturing, antibody drug conjugate production, and related development services, have become the company’s flagship offering and a core reason for its global relevance. In its 2024 segment report, Lonza noted that biologics services generated an EBITDA margin that remained above 30% despite the overall group margin slipping to around 26%, reflecting the higher value and complexity of these projects. The company has invested heavily in flexible manufacturing suites and single use technologies, which allow it to accommodate a wide range of molecule types and scales, from early stage clinical batches to commercial volumes.

The expansion in Visp for payload linker manufacturing, combined with earlier investments in microbial and mammalian facilities in Europe, the United States, and Asia, positions Lonza to capture growth linked to the rising number of approved biologics and antibody drug conjugates. For clients, the integrated offering across development, clinical manufacturing, and commercial supply reduces execution risk, and for Lonza, longer term contracts anchor revenue visibility. Investors therefore monitor metrics such as project count growth, capacity utilization rates, and the share of revenue coming from commercial stage biologics, all of which influence future earnings power and support the investment thesis behind Lonza Group stock.

Shares near CHF 450 level

As of 12 August 2026, Lonza Group stock around CHF 450 per share on SIX Swiss Exchange sits closer to the middle of its 52 week trading range, which spans from roughly CHF 420 at the low to about CHF 520 at the high. Daily liquidity remains robust, with average trading volume of several hundred thousand shares per session according to exchange data, and the stock’s inclusion in the Swiss Market Index ensures that it features in many passive and benchmark driven portfolios. For now, the price level reflects a balance between caution after the 2025 guidance cut and confidence in the long term growth potential of biologics and advanced therapies.

Lonza Group at a glance

• Company: Lonza Group Ltd.
• ISIN: CH0013841017
• Ticker: SIX: LONN
• Trading venue: SIX Swiss Exchange
• Price (as of 12 August 2026, 16:00 CET): 450.00 CHF
• Market capitalization: 38.0 billion CHF (as of 12 August 2026)
• Sector / Industry: Health Care / Pharmaceuticals, Biotechnology and Life Sciences
• Index membership: Swiss Market Index (SMI)